Pregabalin Versus Gabapentin Opioid Sparing Effect in Discectomy
NCT ID: NCT05539924
Last Updated: 2022-10-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
72 participants
INTERVENTIONAL
2022-09-15
2022-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Preoperative intramuscular injection of morphine could reduce the patients' pain during the percutaneous transformational endoscopic discectomy "PTED" surgery and improve the patients' satisfaction without affecting the surgical outcome. The efficacy of adding pregabalin or gabapentin to preoperative intramuscular morphine is not yet investigated.
The current study aims to compare the analgesic effect of both drugs when given preoperatively with intramuscular morphine.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pregabalin Compared to Gabapentin for Pain Control in Lumbar Disc Surgery
NCT02120703
Perioperative Administration of Gabapentin for Reducing Inhalational Anesthetic Consumption
NCT05301205
The Effect of Gabapentin on Spinal Anesthesia Duration
NCT05659810
Management of Pain Associated With Failed Back Surgery Syndrome
NCT05324761
Effect of Pregabalin on Immediate Post-operative and Longterm Pain
NCT02464813
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Informed consent will be obtained from the entire patient enrolled in this study on the day before surgery. VAS score will be explained to all the patients' Visual analogue scale to measure post-operative pain.
VAS is usually a horizontal line, 100 mm in length, anchored by word descriptors at each end.
The patient marks on the line the point that they feel represents their perception of their current state. On the day of surgery, study drug was given orally 1 hour before the time of induction of anesthesia.
In the operation theatre, baseline heart rate, oxygen saturation, and mean arterial blood pressure were recorded. After insertion of a wide bore cannula, and premeditations will be given including anxiolytics e.g. midazolam (70-80mcg/kg) not to exceed \>5mg and Ondansteron (4mg)
Then the patients will be randomized into one of the following three groups:
Group P: The patients in this group will receive 150 mg pregabalin tablets P.O 1 hour before surgery then after half hour morphine 0.1 mg/kg will be administered intramuscularly.
Group G: The patients in this group will receive 400 mg Gababentin4 tablets P.O 1 hour before surgery then after half hour morphine 0.1 mg/kg will be administered intramuscularly.
Group C: The patients in this group will receive vitamin B12(100µg) as placebo tablets P.O 1 hour before surgery then after half hour morphine 0.1 mg/kg will be administered intramuscularly.
The patients enrolled in the study will be transferred to Operation room and monitored all through the surgical procedure using pulse oximeter, non-invasive blood pressure, ECG, capnogram. Patient will be preoxygenated with 100% oxygen for 3 minutes prior to induction. Induction of Anaesthesia will be done using propofol (2mg/kg), Fentanyl (1mcg/kg) and Atracrium (0.5 mg/kg) then Endotracheal intubation will be inserted smoothly using Oral ETT (ID 7.5mm in adult male and ID 7 mm in adult female) then position of Endotracheal tube will be confirmed with auscultation and Capnography.
Anaesthesia will be maintained using 1.2 % isoflurane (that will be adjusted according to hemodynamics changes) with top up doses of atracurium (0.1 mg/kg) every 30 minutes.
Ventilation will be maintained using volume controlled mode with the following parameters:
Tidal volumes 6-8 ml/kg, Respiratory Rate 12 breath/minute to achieve end tidal CO2 between 30 to 35 mmHg.
Intraoperative hemodynamics including heart rate, blood pressure (Systolic, Diastolic and Mean Arterial pressure) will be measured as baseline before induction, after ¼ hour from intubation, before and after the patient being in prone position and every ½ hour.
The patient will be positioned in prone position and precautions of this position will be applied, if Intraoperative hemodynamic changes happened more than 20% or 25% from baseline hemodynamic readings due to lack of analgesia, we will administer(0.5-1 mic.) Fentanyl as rescue analgesia.
At the End of the operation the patient will be returned to supine position and awaked fully reversed with injection of neostigmine and Atropine, and the patients will be extubated and shifted to Recovery room and we will check hemodynamics including heart rate and systolic, diastolic, mean arterial blood pressure, assess VAS scale and requirement of rescue analgesia (morphine) in zero hour then the patients will be transferred to the ward and reassess hemodynamics, the VAS scale and requirement of rescue analgesia after two hours, four hours, six hours, eight hours, ten hours, twelve hours, sixteen hours, twenty hours and twenty four hours respectively.
Postoperative pain assessment through VAS will be according to the scale as follow:
* Pain level 0: no pain
* Pain level1-3: mild pain
* Pain level 4-6: moderate pain
* Pain level 7-10: severe pain
1\. Postoperative pain will be managed as follow:
* Mild pain will be treated with paracetamol 1 gm. IV.
* Moderate pain will be treated with paracetamol 1 gm. IV \& ketolac 30 mg IV.
* Severe pain will be treated with morphine 3mg (rescue analgesia). Then patient will be reassessed and recorded as mentioned above and the specific treatment will be repeated after 8 hours from the initial dose according to VAS.
2\. Opioids complications such as respiratory depression will be recorded and managed supportively by oxygen mask, controlled airway and if persistent or severe hypoventilation occurs positive pressure ventilation may be needed, nausea and vomiting will be treated with ondansterone (4 mg IV).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group P
The patients in this group will receive 150 mg pregabalin tablets P.O 1 hours before surgery then after half hour morphine 0.1 mg/kg will be administered intramuscularly.
Pregabalin 150mg gabapentin 400mg
oral administration
Group G
The patients in this group will receive 400 mg Gababentin4 tablets P.O 1 hours before surgery then after half hour morphine 0.1 mg/kg will be administered intramuscularly.
Pregabalin 150mg gabapentin 400mg
oral administration
Group C
The patients in this group will receive vitamin B12 (100µg) as placebo tablets P.O hours before surgery then after half hour morphine 0.1 mg/kg will be administered intramuscularly.
Pregabalin 150mg gabapentin 400mg
oral administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pregabalin 150mg gabapentin 400mg
oral administration
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Elective Lumber micro discectomy.
* BMI ≤ 35
* Time of operation not exceeding 2hours.
Exclusion Criteria
* Age \< 20 years or \> 60 years
* ASA III to ASA IV
* Contraindications to Opioids e.g., Allergy, Bronchial asthma.
* Contraindication to Pregabalin or Gabapentin e.g. Allergy
* Psychological or mental disorders.
* Disturbance of Conscious level.
* Uncooperative patients.
* Patients with impaired renal function or creatinine clearance less than 50ml/min
20 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Research Institute of Ophthalmology, Egypt
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
mohamed s arafa, MD
Role: STUDY_DIRECTOR
kasr el aini H
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
kasr el aini H
Giza, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
00arafa00
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.